MINERVA IMAGING
Live / Applied — Response to non-final action entered (as of 19 Feb 2026)
What this means for you
Not registered yet, but its 03 Feb 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79418919
- Mark type
- Stylized text
- Filed
- 03 Feb 2025
- Attorney of record
- David M. Janet
Goods and services
- Class 040 — Treatment of materials: Custom manufacture of pharmaceuticals for the treatment of cancer.
- Class 042 — Scientific and technological services: Pharmaceutical drug development services in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research of pharmaceuticals to treat cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research relating to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical research and development related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research on the subject of pharmaceuticals for cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical research services in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; clinical research and conducting clinical trials in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; conducting clinical trials for pharmaceutical products in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials for cancer, cardiovascular disease, and cell therapy, including stem cell therapy; providing information about the results of clinical trials for pharmaceutical products related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical products development related to the treatment of cancer and cardiovascular disease; consulting services for others in the field of designing clinical trials related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; scientific and technical consulting and research services for the pharmaceutical industry in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy.
Owner
Prosecution history
- 19 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 19 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 19 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 05 Sept 2025 — REFUSAL PROCESSED BY IB
- 21 Aug 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 21 Aug 2025 — REFUSAL PROCESSED BY MPU
- 18 Jul 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 17 Jul 2025 — NON-FINAL ACTION WRITTEN
- 14 Jul 2025 — ASSIGNED TO EXAMINER
- 23 May 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 16 Mar 2025 — APPLICATION FILING RECEIPT MAILED
- 16 Mar 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 13 Mar 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB